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Carriagea b s t r a c t
Background: Aboriginal children in Northern Australia have a high burden of otitis media, driven by early
and persistent nasopharyngeal carriage of otopathogens, including non-typeable Haemophilus influenzae
(NTHi) and Streptococcus pneumoniae (Spn). In this context, does a combined mixed primary series of
Synflorix and Prevenar13 provide better protection against nasopharyngeal carriage of NTHi and Spn ser-
otypes 3, 6A and 19A than either vaccine alone?
Methods: Aboriginal infants (n = 425) were randomised to receive SynflorixTM (S, PHiD-CV10) or Prevenar13TM
(P, PCV13) at 2, 4 and 6 months (_SSS or _PPP, respectively), or a 4-dose early mixed primary series of PHiD-
CV10 at 1, 2 and 4months and PCV13 at 6months of age (SSSP). Nasopharyngeal swabs were collected at 1, 2,
4, 6 and 7 months of age. Swabs of ear discharge were collected from tympanic membrane perforations.
Findings: At the primary endpoint at 7 months of age, the proportion of nasopharyngeal (Np) swabs positive
for PCV13-only serotypes 3, 6A, or 19A was 0%, 0.8%, and 1.5% in the _PPP, _SSS, and SSSP groups respectively,
and NTHi 55%, 52%, and 52% respectively, and no statistically significant vaccine group differences in other
otopathogens at any age. The most common serotypes (in order) were 16F, 11A, 10A, 7B, 15A, 6C, 35B,
23B, 13, and 15B, accounting for 65% of carriage. Ear discharge swabs (n = 108) were culture positive for
NTHi (52%), S. aureus (32%), and pneumococcus (20%).
Conclusions: Aboriginal infants experience nasopharyngeal colonisation and tympanicmembrane perforations asso-
ciated with NTHi, non-PCV13 pneumococcal serotypes and S. aureus in the first months of life. Nasopharyngeal car-
riage of pneumococcus or NTHiwas not significantly reduced in the early 4-dose combined SSSP group compared to
standard _PPP or _SSS schedules at any time point. Current pneumococcal conjugate vaccine formulations do not
offer protection from early onset NTHi and pneumococcal colonisation in this high-risk population.
 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
Remote-dwelling Aboriginal and Torres Strait Islander (here-
after respectfully termed Indigenous) children in Australia have a
high burden of infectious disease. Otitis media (OM), which com-
mences at a younger age, is more likely to progress to complica-
tions (perforations, chronicity and hearing loss) in this
population [1]. On average almost 20% children have chronic sup-
J. Beissbarth, N. Wilson, B. Arrowsmith et al. Vaccine 39 (2021) 2264–2273purative otitis media (CSOM) or acute otitis media with perforation
(AOMwiP) at 18 months of age [2–4]. The predominant bacterial
pathogens associated with early onset of persistent OM in this pop-
ulation are non-typeable Haemophilus influenzae (NTHi) and Strep-
tococcus pneumoniae (Spn) [5]. Colonisation of the nasopharynx by
Spn, NTHi and other potentially pathogenic bacteria occurs within
the first weeks of life [5,6]. NTHi is the dominant bacterial patho-
gen cultured from discharging ears [7].
A pneumococcal conjugate vaccine (PCV) program commenced in
Australia in 2001 for Indigenous infants and in 2005 for non-
Indigenous infants with Prevenar7TM (PCV7). The Northern Territory
(NT) then moved to SynflorixTM (PHiD-CV10) in 2009 and Prevenar
13TM (PCV13) in 2011. In the NT [8–11], more than 90% of infants have
completed their 3 dose primary series by 12–15 months of age.
During the two year PHiD-CV10 era in the NT, there was a sig-
nificant reduction in NTHi cultured from ear discharge (compared
to PCV7 era), with no corresponding reduction in Np NTHi carriage
[12]. International trials had previously shown that vaccine effi-
cacy against tympanocentesis-confirmed NTHi-AOM in the 11PnPd
precursor vaccine trial (POET) in Czech and Slovakian infants was
35%. The effect on carriage was small and a non-significant trend
of reduced carriage compared to the control group carriage became
significant only post booster dose, for any H. influenzae (18/177,
10.2% vs 31/175, 17.7%, p = 0.046) [13,14]. In the more recent COM-
PAS trial, there was lower Np carriage than predicted (4–6% over all
age groups 12–27 months), and no reduction in carriage was
detected, including post-booster dose [15].
Post-PCV7 introduction in Australia, whilst there was no change
in overall carriage, there was a reduction in PCV7 serotype carriage
and disease. Due to serotype replacement, an increased prevalence
of pneumococcal serotype 19A was reported in carriage in Western
Australian Aboriginal children [16], and nationwide a four-fold
increase in 19A-invasive pneumococcal disease in children under
5 years old [17], likely preceded by carriage. As only PCV13
includes 19A, a study was designed that would use the two current
pneumococcal conjugate vaccines in combination, to derive benefit
from both formulations.
We undertook a 3-arm randomised controlled trial to compare
immunogenicity, safety, clinical and microbiological outcomes fol-
lowing standard 2-4-6 month schedules of PHiD-CV10, PCV13, or a
novel early start mixed primary schedule of PHiD-CV10 at 1, 2, and
4 months followed by PCV13 at 6 months [18]. In the primary out-
come paper we demonstrated that the combination schedule was
immunogenic against all vaccine serotypes including the PCV13-
only serotypes 3, 6A, and 19A and the PHiD-CV10-only non-
typeable Haemophilus influenzae protein D at 7 months of age.
These responses in the combination group were not significantly
lower than the responses to either vaccine alone [19].
In this publication we report the priority Np and ear discharge
microbiological outcomes by vaccine randomisation group. These pri-
marymicrobiological objectives were to determine whether the com-
bination schedule provides i) significant difference in Np carriage of
PCV13-vaccine-only serotypes 3, 6A, and 19A compared to PHiD-
CV10 alone, ii) significant difference in Np carriage of NTHi compared
to PCV13 alone, one month post primary schedule, at 7 months of
age, and iii) describe early life Np carriage and ear discharge respira-
tory pathogen bacteriology and antimicrobial resistance.2. Methods
2.1. Study design and participants
This assessor blinded randomised controlled trial enrolled 425
Australian Indigenous (1:1:1) infants from 5 remote Aboriginal
communities in the Northern Territory and Western Australia to2265receive either PHiD-CV10 (S) or PCV13 (P) at 2, 4 and 6 months
(_SSS or _PPP), or an early start novel combination schedule of
PHiD-CV10 at 1, 2 and 4 months and PCV13 at 6 months (SSSP) [18].
This trial was registered with ANZCTR (ACTRN12610000544077)
and ClinicalTrials.gov (NCT01174849). Ethical approval for the trial
was provided by the Human Research Ethics Committee of the North-
ern Territory Department of Health & Families and the Menzies
School of Health Research (HREC - EC00153), ref: HREC-2010-1395,
Central Australian Human Research Ethics Committee (CAHREC -
EC00155), ref: 2010.06.02, West Australian Aboriginal Health Infor-
mation Ethics Committee (WAAHIEC) ref: 377-12/2011, and theWes-
tern Australia Country Health Service Ethics (WACHS), ref: 2012:17.
2.2. Procedures
Data collection began in September 2011 and was completed in
May 2018. The published study protocol [18] outlines all study
procedures. Briefly, Np swabs were collected at 1, 2, 4, 6 and
7 months (Fig. 1). Primary endpoint samples were collected at least
28 days post 6-month dose. Ear discharge swabs were collected
when discharge was observed during the otoscopic examination
or at tympanometry, from both AOMwiP (defined as discharge of
pus through a small perforation (hole) in the eardrum within the
last 6 weeks) and CSOM (persistent ear discharge for at least
6 weeks through a perforation of >2% of the pars tensa). All samples
were collected and stored as per WHO guidelines for pneumococ-
cal trials [20]. In brief, a 10 ml aliquot of the Np swab in STGGB was
plated using a semi-quantitative method onto selective and non-
selective media to isolate Spn, NTHi, Moraxella catarrhalis (Mc)
and Staphylococcus aureus (Sa). Swabs collected from infants at
ages 1, 2, and 4 months had two additional aliquots of 50 ml plated
on Spn and NTHi selective media for the retrieval of low density
carriage. Swabs were coded as positive if the bacteria of interest
were grown from either the 50 ml spread plates or the semi-
quantitative plates. Capsular Spn were identified by morphology,
optochin resistance and a positive Quellung reaction (Statens
Serum Institute of Copenhagen, Denmark). Throughout the manu-
script ‘Spn’ refers to capsular Spn only. Presumptive NTHi were
identified by morphology, X and V dependence (Oxoid) and coag-
glutination negative (Haemophilus Phadebact, Remel). NTHi iso-
lated from ear discharge samples were confirmed as H. influenzae
by PCR to differentiate them from non-haemolytic H. haemolyticus.
Np NTHi isolates were not speciated by molecular methods, as only
0.34% of Np NTHi isolates from this population are misidentified
Hh [21]. Mc were identified by morphology, oxidase production
and Gram stain. Sa were identified by colony morphology and
coagulation by latex agglutination (Staphaurex, Remel). beta-
lactamase production by NTHi and Mc was determined using nitro-
cephin (Oxoid, Australia). Spn (oxacillin, penicillin, tetracycline,
erythromycin, sulphamethoxazole trimethoprim, chlorampheni-
col) and Sa (oxacillin, penicillin, erythromycin, cefoxitin, gentam-
icin, ciprofloxacin) had antimicrobial susceptibility screening by
Calibrated Dichotomous Sensitivity (CDS) [22]. If Spn isolates were
non-susceptible to penicillin or erythromycin, the MIC was deter-
mined by Etest (bioMerieux, Australia). Resistance breakpoints
for penicillin and azithromycin are according to EUCAST guidelines
(penicillin sensitive  0.06 mg/l, intermediate > 0.06 and  2 mg/l,
resistant > 2 mg/l; azithromycin sensitive  0.25 mg/l,
intermediate > 0.25 and  0.5 mg/l, resistant > 0.5 mg/l).
For NTHi, Mc and Sa, one colony was arbitrarily selected from
the primary culture, plus any morphologically distinct colony
types. Two arbitrarily colonies of the dominant morphotype of
Spn were selected, plus any morphologically distinct colony types.
The guardian of the child, (usually the biological mother) was
interviewed using a standardised risk-factor questionnaire when
the child was 1 and 6 months of age.
425 Randomised at 1 month of age*
141 allocated to Synflorix 141 allocated to combination  143 allocated to Prevenar




Infants seen (N) = 136 (ITT)
Data available (ITT)
136 Np swab collected
136 ear diagnosis
5 with wet perforaon
5 ED collected




Infants seen (N) = 135 (ITT)
Data available (ITT)
135 Np swab collected
132 ear diagnosis
1 with wet perforaon
1 ED collected




141 included in ATP analysis
Data available (ITT)
82 Np swab collected
140 ear diagnosis
0 with wet perforaon
0 ED collected




129 included in ATP analysis
Data available (ITT)
83 Np swab collected
139 ear diagnosis
0 with wet perforaon
0 ED collected




126 included in ATP analysis
Data available (ITT)
80 Np swab collected
136 ear diagnosis
0 with wet perforaon
0 ED collected




Infants seen (N) = 135 (ITT)
Data available (ITT)
135 Np swab collected
133 ear diagnosis




















Infants seen (N) = 141 (ITT)
Data available (ITT)
140 Np swab collected
137 ear diagnosis
0 with wet perforaon
0 ED collected




Infants seen (N) = 136 (ITT)
Data available (ITT)
136 Np swab collected
133 ear diagnosis
0 with wet perforaon
0 ED collected




Infants seen (N) = 139 (ITT)
Data available (ITT)
139 Np swab collected
138 ear diagnosis
3 with wet perforaon
3 ED collected




Infants seen (N) = 138 (ITT)
Data available (ITT)
137 Np swab collected
138 ear diagnosis
17 with wet perforaon
16 ED collected




Infants seen (N) = 137 (ITT)
Data available (ITT)
137 Np swab collected
136 ear diagnosis
10 with wet perforaon
10 ED collected




Infants seen (N) = 132 (ITT)
Data available (ITT)
132 Np swab collected
132 ear diagnosis
















Infants seen (N) = 136 (ITT)
Data available (ITT)
136 Np swabs collected
135 ear diagnosis
17 with wet perforaon
17 ED collected




Infants seen (N) = 132 (ITT)
Data available (ITT)
131 Np swab collected
130 ear diagnosis
11 with wet perforaon
6 ED collected   




Infants seen (N) = 136 (ITT)
Data available (ITT)
134 Np swab collected
135 ear diagnosis
10 with wet perforaon
9 ED collected
*1018 mothers assessed for eligibility, 593 excluded [326 ineligible (gestaon<32 weeks, baby >38 days, non-study 
residence, infant deceased, clinician advice, unable to locate / contact mother), 112 miscarriage / sllborn / unknown 
pregnancy outcome, 8 pending birth, 145 refused / unable to contact within window, 2 withdrawn post consent prior to 
randomisaon], 425 randomised 
Fig. 1. Number of infants seen and procedures completed by age and vaccine group.
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J. Beissbarth, N. Wilson, B. Arrowsmith et al. Vaccine 39 (2021) 2264–22732.3. Statistical analysis
The enrolment target of 425 infants had over 90%power to detect
reductions in NTHi and 19A carriage at 7months of age, from 80% to
50% (for NTHi) and 20% to 5% (for 19A), respectively, between the
COMBO group and the PCV13 group (for NTHi), and the COMBO
group and PHiD-CV10 group (for 19A) [13,23,24]. Binomial exact
95% confidence interval was calculated for all carriage outcomes
and two-sidedFisher’s exact test used invaccinegroupcomparisons.
In secondary analyses, these comparisons were also applied to ear
discharge samples and all samples at other timepoints. Data for ser-
otypes 3, 6A, and 19A were aggregated for comparison due to the
small number isolated. Cumulative carriage was calculated using
all swabs, once an infant is observed to be carriage positive (by
organism, Spn, NTHi and Mc) they are counted as positive at their
age in days. New acquisition of a serotype is defined as a serotype
different to the carriage type first isolated in the infant and includes
multiple carriage serotypes counted individually. If multiple car-
riage was observed at the first colonisation the next serotype had
to be different to both isolated serotypes to be counted as a new
acquisition. If a specific serotype was observed in an infant at non-
consecutive visits this was not counted as a new acquisition.Where
there was no difference in serotype or antibiogram the data for the
first isolate only was included in the analyses. For multiple isolates
of the same serotype but different antibiograms, bothwere includedTable 1
Baseline and 7 month characteristics.
Characteristics PCV13 PREVENAR13 (PPP)
N = 143





Mean (SD) 38.4 (1.4)
Birthweight, kg
Mean (SD) 3.2 (0.5)
Weight at randomisation, kg
Mean (SD) 4.3 (0.5)
Age at randomisation, days
Mean (SD) 33.1 (3.3)
Community – total randomisation
Wurrumiyanga (Nguiu) 29 (20.3%)
Wadeye 53 (37.1%)
Kununurra 26 (18.2%)
Alice Springs (CAAC) 7 (4.9%)
Maningrida 28 (19.6%)
Risk factors for OM at visit 1
Family history of TMP (mother) 22 (19.3%)
Family history of TMP (siblings) 19 (19%)
Siblings under 5 years
Median (IQR) 2.0 (1.0–2.0)
Breast fed 120 (96.8%)
Breast fed only 98 (83.8%)
Bottle fed 24 (19.7%)
Bottle fed only 4 (3.3%)
Mother smoked during pregnancy 58 (48.7%)
Others smoked in household 27 (21.8%)
Use cooking fire 23 (18.7%)
Characteristics at 7 months of age
Age in months,
Mean (SD) 7.1 (0.72)
Risk factors for OM at visit 1




Breast fed 110 (90.2%)
Mother smokes 72 (58.5%)
Others smoking at house 30 (24.6%)
Use cooking fire 33 (27.0%)
TMP, tympanic membrane perforation.
2267in the analysis of the antimicrobial sensitivity data. Thus, per swab
data may add to more than 100%. Analyses of ear discharge are pre-
sented per child. Where infants have bilateral ear discharge data
were combined. Logistic regression was used to determine the
impact of time on carriage of PCV13 serotypes, adjusted for cluster-
ing by child with robust SE to understand the herd impact of chang-
ing the infant pneumococcal vaccine schedule to PCV13 in the first
year of the trial. Statistical significancewas set ata  0:05. All statis-
tical analyses were performed using Stata 15 (StataCorp, USA).
Although we have multiple comparisons, no adjustments were
made to significance thresholds.
2.4. Role of the funding source
This study was funded by the National Health and Medical
Research Council (NHMRC) of Australia (GNT605810). The NHMRC
has no input into the study design, collection, analysis, interpreta-
tion of findings or decision to publish these findings.
3. Results
3.1. Demographics and risk factors
Baseline characteristics and prevalence of risk factors were sim-
ilar across the three groups (Table 1). Risk factors for OM remainedPHiD-CV10 SYNFLORIX (SSS) PCV13 and PHiD-CV10 (SSSP)
N = 141 N = 141
69 (48.9%) 70 (49.6%)
72 (51.1%) 71 (50.4%)
38.4 (1.4) 38.1 (1.6)
3.2 (0.5) 3.10(0.5)
4.2 (0.6) 4.0 (0.7)
32.5 (3.8) 32.5 (3.9)
33 (23.4%) 30 (21.3%)
50 (35.5%) 51 (36.2%)
25 (17.7%) 26 (18.4%)
6 (4.3%) 6 (4.3%)
27 (19.1%) 28 (19.9%)
19 (15.7%) 17 (14.4%)
22 (23%) 19 (20%)
2.0 (1.0–2.5) 2.0 (1.0–2.0)
117 (94.4%) 116 (95.9%)
98 (85.2%) 93 (81.6%)
26 (20.8%) 25 (21.0%)
6 (5.0%) 4 (3.4%)
60 (48.4%) 61 (50.8%)
31 (24.8%) 22 (18.2%)
22 (17.6%) 28 (23.1%)
7 (0.66) 7 (0.93)
109 (83.2%) 117 (85.4%)
20 (15.3%) 20 (14.6%)
2 (1.5%) 0 (0.0%)
108 (90.8%) 115 (91.3%)
70 (58.8%) 83 (65.9%)
26 (21.8%) 23 (18.3%)





































































































































95% CI _PPP _SSS SSSP
Fig. 2. Proportions of nasopharyngeal swabs positive for NTHi, combined serotypes 3, 6A and 19A, any PCV13-types, any capsular Spn, any Mc and Sa at ages 1-7mo by
vaccine group with 95% CI.
J. Beissbarth, N. Wilson, B. Arrowsmith et al. Vaccine 39 (2021) 2264–2273similarly distributed between vaccine groups at 6 months of age.
Overall breast feeding at 6 months was 91%, maternal smoking
was 61%, smoke exposure in the home was 22%, and use of a fire
for cooking or social gatherings was 28%. The number of Np and
ear discharge swabs collected at each timepoint by vaccine group
are shown in Fig. 1.
3.2. Primary microbiology outcomes:
3.2.1. Np carriage of 3, 6A, and 19A and NTHi by vaccine group at
7 months of age
Of the PCV13 exclusive serotypes only two isolates of serotype
3, four isolates of 6A, and 31 isolates of 19A were cultured from Np
swabs over the life of the study. There were no statistically signif-
icant differences for the primary outcomes of combined Np car-
riage prevalence of serotypes 3, 6A, or 19A in the SSSP group
compared to the SSS group (0% vs 0.8%; p = 0.491), or NTHi carriage
in the SSSP group compared to the _PPP group (52% vs 52%, p = 1)
at 7 months of age (Fig. 2, Table 2).
The use of a 50 ml inoculum (compared to 10 ml) for infants aged
1, 2 or 4 months slightly improved the Np carriage detection, par-
ticularly for NTHi (up to 5%). These additional positives are
included in all reporting.
3.3. Secondary microbiology outcomes
3.3.1. Np carriage overall
A total of 1873 Np swabs were collected. Overall, 1159 Spn iso-
lates were serotyped. One Np swab was not able to be assessed for
NTHi and Mc due to swarming overgrowth.
Overall Np carriage of Mc was 70%, Spn 58%, NTHi 53%, and Sa
18%. Carriage of Hi type B was 1.3% and capsule types a, c-f 3.3%.
Proportions by age and overall are reported in Table 2, with all vac-2268cine group comparisons. The cumulative proportion of infants with
Np carriage of Spn, NTHi and Mc is presented in Fig. 3; Mc was
acquired first, followed by Spn and NTHi acquisition from a similar
age. Cumulatively 92%, 91% and 96% were positive for Spn, NTHi
and Mc respectively by age 7 months.
Of the ten serotypes common to both vaccines, no isolate of ser-
otypes 1, 5 or 7F was cultured. The most common vaccine types
were 19F (3%), 19A (3%), 23F (3%) and 9 V (1%). PCV13-VTs declined
during the study period, from 15% of isolates (9% of Np swabs) col-
lected in 2012 to 8% of isolates (4% of Np swabs collected) in 2017–
18. Serotype 19A was 3% of isolates (2% of Np swabs) in 2012 and
0.5% of isolates (0.3% of Np swabs) in 2017–18. For vaccine groups
combined, in a logistic regression, adjusted for clustering by child,
there was a statistically significant temporal trend of declining Np
carriage of PCV13-types from 9% to 4% between late 2011 to May
2018 (OR 0.840, 95%CI 0.617–0.900 p = 0.029). Carriage was dom-
inated by non PCV13 vaccine serotypes (1032/1159, 89%), the most
common types were 16F (15%), 11A (9%), 10A (6%), 7B (6%) and 6C
(5%) (Fig. 4, Table 2).
Concurrent carriage of Spn, NTHi and Mc was 7%, 22%, 33%, 33%
and 30% of swabs at 1, 2, 4, 6 and 7 months respectively. At one
month of age the most prevalent colonisation pattern was Sa alone
(23%), and co-colonisation with Spn, NTHi and Mc was the most
common pattern at all other ages. At each age, more than 40% of
infants had two or more co-colonising respiratory pathogens.
3.3.2. Np carriage of vaccine serotypes by age and vaccine group
At 1 month of age, pre-vaccination, combined Np carriage of
serotypes 3, 6A, or 19A in the PPP, _SSS, and SSSP groups respec-
tively was 1.2%, 2.4%, and 0%. At 2 months of age, carriage was
6%, 0.7%, and 2%, and the difference between the non-vaccinated
groups was significant (p = 0.036). There were no other significant
between group differences at any time point (Table 2).
Table 2
Number of nasopharyngeal swabs positive and percent (%) by vaccine group for NTHi positive swabs and swabs positive for serotypes, 3, 6A and 19A, any PHiD-CV10 types, any
PCV13 types, any capsular Spn and any non-VT Spn.
Category Age (mo) N, number positive, percent (%) per group
N _PPP % N _SSS % N SSSP % Total (%)
NTHi pos 1 82 25 (30.5) 83 25 (30.1) 80 25 (31.3) (30.7)
2 140 77 (55) 136 76 (55.9) 139 63 (45.3) (52.1)
4 136 86 (63.2) 135 81 (60) 135 82 (60.7) (61.3)
6 136 76 (55.9) 131 84 (64.1) 133 83 (62.4) (60.6)
7 137 71 (51.8) 132 73 (55.3) 136 71 (52.2) (53)
Any 3, 6A, 19A 1 82 1 (1.2) 83 2 (2.4) 80 0 (0) (1.2)
2 140 8 (5.7) 136 1 (0.7) 139 3 (2.2) (2.9)
4 136 5 (3.7) 135 4 (3) 135 3 (2.2) (2.7)
6 136 3 (2.2) 131 2 (1.5) 133 3 (2.3) (2.0)
7 137 2 (1.5) 132 1 (0.8) 136 0 (0) (0.7)
Any PHiD-CV10 VT Spn 1 82 4 (4.9) 83 2 (2.4) 80 1 (1.3) (2.9)
2 140 14 (10) 136 4 (2.9) 139 5 (3.6) (5.5)
4 136 13 (9.6) 135 8 (5.9) 135 5 (3.7) (6.4)
6 136 10 (7.4) 131 6 (4.6) 133 3 (2.3) (4.5)
7 137 8 (5.8) 132 5 (3.8) 136 5 (3.7) (3.9)
Any PCV13 VT Spn 1 82 5 (6.1) 83 4 (4.8) 80 1 (1.3) (4.1)
2 140 21 (15) 136 5 (3.7) 139 8 (5.8) (8.2)
4 136 18 (13.2) 135 12 (8.9) 135 8 (5.9) (9.1)
6 136 13 (9.6) 131 8 (6.1) 133 6 (4.5) (6.5)
7 137 10 (7.3) 132 6 (4.5) 136 5 (3.7) (4.7)
Capsular Spn 1 82 26 (31.7) 83 31 (37.3) 80 24 (30) (33.1)
2 140 80 (57.1) 136 66 (48.5) 139 76 (54.7) (53.5)
4 136 86 (63.2) 135 89 (65.9) 135 85 (63) (64)
6 136 86 (63.2) 131 88 (67.2) 133 85 (63.9) (64.8)
7 137 85 (62) 132 86 (65.2) 136 90 (66.2) (64.3)
Any non-VT Spn 1 82 22 (26.8) 83 27 (32.5) 80 23 (28.8) (30)
2 140 62 (44.3) 136 61 (44.9) 139 68 (48.9) (45.8)
4 136 69 (50.7) 135 78 (57.8) 135 78 (57.8) (55.7)
6 136 74 (54.4) 131 81 (61.8) 133 81 (60.9) (59.4)
7 137 77 (56.2) 132 80 (60.6) 136 85 (62.5) (60.1)
Bold type indicates p-value < 0.05 for group comparisons (Fisher’s exact test); Culture of 50 ml added 10 positives for Spn, 1(0.4%), 7 (2%) and 2(0.5%); 41 for NTHi, 6(2%), 13
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Fig. 3. Cumulative proportion of children positive for the otopathogens Spn, NTHi
and Mc by age.
J. Beissbarth, N. Wilson, B. Arrowsmith et al. Vaccine 39 (2021) 2264–2273At 2 months of age, one month after first dose of PHiD-CV10 in
the SSSP group, Np carriage of ten common serotypes was not sig-
nificantly lower in the SSSP group (3.6%) compared to either of the
non-vaccinated groups (10% and 2.9%). However, as with 3, 6A and
19A, the difference in Np carriage of ten common serotypes
between non-vaccinated groups was statistically significant (10%
vs 2.9%; p = 0.026). This difference was not sustained at subsequent
timepoints.
At 4 months, following two doses of PHiD-CV10 in the SSSP
group compared to single doses in the _PPP and _SSS groups, Np2269carriage of PCV13 serotypes remained highest in the _PPP group
at 13.2% compared to 8.1%, and 5.9% in _SSS and SSSP groups but
differences were non-significant (p = 0.062). Differences at other
timepoints were also non-significant.3.3.3. Np carriage of non-PCV13 types
Over all ages, Np carriage of non-PVC13 types was 48%, 54% and
54% in the _PPP, _SSS and SSSP groups, respectively. There were no
statistically significant differences at any age (Fig. 2, Table 2). There
was a transient significant difference in proportion positive for ser-
otype 6C at 6 months of age, between the SSSP group (0.7%) and
the _SSS group (5.3%), p = 0.035.3.4. Antimicrobial sensitivity for Spn and NTHi
Antimicrobial testing (Fig. 4) showed that overall 52% of the
capsular isolates were sensitive, 47% were non-susceptible and
1% were resistant to penicillin; while 71% were sensitive and 29%
were resistant to azithromycin. At age 7 months, the proportion
of infants with an azithromycin resistant isolate was lower in the
_PPP group compared to the SSSP group (15.3% vs 27.7%;
p = 0.018) but not the _SSS group (15.3% vs 24.2%; p = 0.091). There
were no other between group differences in antimicrobial sensitiv-
ity at any age (data not shown).
At a serotype level, over 90% of 7B and 15A isolates were macro-
lide resistant (Fig. 4). The resistance pattern was largely found
among infants living in two specific regions during 2012/13 for
15A and 2013/14 for 7B.
Approximately 9% of NTHi positive swabs had a b-lactamase
producing isolate.
Table 3
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Fig. 4. Percent of isolates with sensitivity to penicillin and azithromycin, in order of PCV7, PHiD-CV10 and PCV13 types, followed by hierarchy of remaining serotypes.
J. Beissbarth, N. Wilson, B. Arrowsmith et al. Vaccine 39 (2021) 2264–22733.5. Serotype carriage patterns, new acquisitions, and multiple
carriage
Of the 425 infants randomised, at least one Np swab was col-
lected from 422 infants, 33 of whom were negative for capsular
Spn or did not contribute swabs at all timepoints. There were 60
(3%) swabs with two different serotypes isolated, one had three
serotypes. Of the 389 infants with serotype data, 20 infants had a
serotype at all five study visits. Consecutive carriage of the same
serotype at 2 or more visits was seen in 166 infants for 2 visits,
43 for 3 visits, 12 for 4 visits and 2 for 5 visits. Consecutive sero-
types at 3 or more visits are shown in Table 3. Serotype 19F was
the only vaccine serotype to be detected at 3 or more consecutive
visits. The remaining infants had different serotypes or were Spn-
negative visit to visit.3.6. NP carriage and antimicrobial sensitivity of other otopathogens
Np carriage of NTHi by age and vaccine group (Fig. 2), as
reported in Table 2 shows no statistically significant
differences.
There were no statistically significant differences at any time
point between the vaccine groups for carriage of either Sa or Mc
(Fig. 2). Almost all (97%) of the Mc positive swabs (97% of infants)
had a b-lactamase producing Mc isolate. Overall, 22% of the Sa pos-
itive swabs (4% infants) had a cefoxitin resistant isolate.22703.7. Ear discharge swabs
Overall, 108 swabs were collected from 124 discharging ears in
57 infants (13%) visited between 2 and 7 months of age; 74 swabs
were from AOMwiP and 34 were from CSOM. At least one pathogen
was isolated in 40 of the 57 infants. One ear discharge swab was
not able to be assessed for NTHi and Mc due to swarming
overgrowth.
3.7.1. Ear discharge culture at the primary 7 month endpoint, by
vaccine group
There were 17, 12 and 10 infants with ear discharge in the _PPP,
_SSS and SSSP groups 7 months of age (9%). None were culture pos-
itive for serotypes 3, 6A, or 19A at this age. There were no signifi-
cant vaccine group differences (Table 4), other than an unexpected
difference in NTHi-positive ear discharge at 7 months between the
_SSS and SSSP groups (3/11, 27.3% vs 8/10, 80%; p = 0.030) but the
low numbers limit robust interpretation.
3.7.2. Ear discharge culture-positive swabs by pathogen and age,
vaccine groups combined
By age, ear discharge swabs were positive for Spn in up to 23%
and NTHi in up to 61% of infants with perforated tympanic mem-
branes. Sa declined from 100% at 2 months of age to 26% at
7 months of age. NTHi was the most common ear discharge patho-
gen detected in either AOMwiP or CSOM (48% and 51%, respec-
tively) (Table 4, Fig. 5). Among 22 Spn isolates cultured from 19
ear discharge swabs taken from 15 infants the serotype hierarchy
was 16F(4) and 7B(4, all from one infant), 11A(2), 13(2), 15A(2),
19A(2), 19F(2), 33F(2), 10A(1) and 33B(1). Mixed serotype infec-
tions were detected on several occasions but are not described
here.4. Discussion
4.1. Nasopharyngeal carriage
In this 3-arm trial of a head to head comparison of PCV13 and
PHiD-CV10 standard 3-dose schedules, and comparison with a
novel 4-dose early combination of PHiD-CV10 at 1, 2 and 4 months
plus PCV13 at 6 months we found no difference in primary micro-
biological outcomes between the SSSP and _PPP groups (for NTHi),
Table 4
Vaccine group comparisons of ED culture-positive for NTHi, serotypes 3, 6A, and 19A, any PCV13 types, any capsular Spn, any Sa, or Spn and NTHi co-colonisation.
Category Age (mo) N, number positive, percent (%) per group Total (%)
N _PPP % N _SSS % N SSSP %
NTHi 2 0 0 (0) 1 0 (0) 2 0 (0) (0)
4 5 3 (60) 1 1 (100) 4 2 (50) (60)
6 16 6 (37.5) 6 3 (50) 9 5 (55.6) (45.2)
7 17 12 (70.6) 11 3 (27.3) 10 8 (80) (60.5)
Any 3, 6A, 19A 2 0 0 (0) 1 0 (0) 2 0 (0) (0)
4 5 0 (0) 1 0 (0) 4 0 (0) (0)
6 16 0 (0) 6 1 (16.7) 9 0 (0) (3.2)
7 17 0 (0) 11 0 (0) 10 0 (0) (0)
Any PCV13 VT Spn 2 0 0 (0) 1 0 (0) 2 0 (0) (0)
4 5 1 (20) 1 0 (0) 4 0 (0) (10)
6 16 0 (0) 6 1 (16.7) 9 0 (0) (3.2)
7 17 1 (5.9) 11 0 (0) 10 0 (0) (2.6)
Capsular Spn 2 0 0 (0) 1 0 (0) 2 0 (0) (0)
4 5 1 (20) 1 0 (0) 4 0 (0) (10)
6 16 2 (12.5) 6 2 (33.3) 9 3 (33.3) (22.6)
7 17 3 (17.6) 11 1 (9.1) 10 4 (40) (21.1)
Sa 2 0 0 (0) 1 1 (100) 2 2 (100) (100)
4 5 2 (40) 1 0 (0) 4 2 (50) (40)
6 16 3 (18.8) 6 1 (16.7) 9 4 (44.4) (25.8)
7 17 6 (35.3) 11 0 (0) 10 5 (50) (29)
Capsular Spn & NTHi 2 0 0 (0) 1 0 (0) 2 0 (0) (0)
4 5 1 (20) 1 0 (0) 4 0 (0) (10)
6 16 1 (6.3) 6 2 (33.3) 9 2 (22.2) (16.1)
7 17 2 (11.8) 11 0 (0) 10 4 (40) (15.8)
Bold type indicates p-value < 0.05 for group comparisons (Fisher’s exact test); Culture of 50 ml added 1(10%) additional Sa positive. At 2, 4, 6 and 7 months respectively there
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Fig. 5. Proportion of ear discharge swabs positive for Spn, NTHi, Mc and Sa, by ear
diagnosis, vaccine groups combined.
J. Beissbarth, N. Wilson, B. Arrowsmith et al. Vaccine 39 (2021) 2264–2273or SSSP and _SSS groups (for serotypes 3, 6A and 19A). There were
no significant vaccine group differences in Np carriage of other
pathogens investigated at the primary 7 month endpoint.
This study highlights the ongoing early life Np colonisation by
multiple otopathogens. Prevalence of Np carriage at 7 months of
age was 64% for Spn, 53% for NTHi, 73% for Mc and 5% for Sa. Inter-
estingly, Np carriage of Mc was higher than NTHi or Spn at 1 month
of age indicating earlier colonisation or detection; however, almost
no Mc was found in ear discharge. Although comparisons with his-
torical data are less reliable, current prevalence may be lower than
previously reported from this population. An RCT in 1994–2000
reported higher carriage prevalence for Spn (80%) and NTHi (77%)
[23], and 2012–13 cross-sectional data from Indigenous children
(mean age 16 months) detected 80%, 70% and 44% carriage of
Spn, NTHi and Mc respectively and 19% Sa [12]. While current data
indicate a decrease in Np carriage of Spn and NTHi, these rates are
still high confirming ongoing early exposure to multiple bacterial2271respiratory pathogens. A major driver is likely to be household
crowding, which continues to be a priority issue in remote
communities.
We report low Np carriage rates of serotypes 3 (0.2%) and 6A
(0.4%) and 19A (3%) overall. While this is consistent with our pre-
vious studies for serotype 3, [4,12] we expected higher carriage for
6A and 19A. Our power and sample size estimates predicted that
the study was powered to detect a 15% absolute difference in
19A carriage, from 20% to 5%. During the course of this RCT with
the introduction of PCV13 in the NT, surveillance indicated reduc-
tions in 19A carriage, limiting power to capture vaccine group
differences.
There was an overall low percentage of all PCV13 serotypes iso-
lated during this trial. PCV13-type carriage decreased slowly, but
significantly over the course of the study. There was unexpectedly
significantly higher PCV13-VTs in the _PPP group compared to both
the _SSS and SSSP groups at 2 months, and the _PPP group contin-
ued to have higher (non-significant) carriage of PCV13 vaccine ser-
otypes than _SSS and SSSP at 4, 6, and 7 months. This is an
interesting observation as immunogenicity data from this study
showed significantly lower IgG GMCs in the _PPP group to most
PCV serotypes at 4 months [19].
A diversity of non-vaccine serotypes play an important role in
otitis media in this population. Serotype 16F has been uniquely
dominant in the NT but has not been the target of any expanded
valency vaccine development.
We found reduced carriage and middle ear infection caused by
vaccine type pneumococci, as had been reported previously
[12,24], replaced in carriage and middle ear infection by numerous
non-PCV Spn serotypes.4.2. Ear discharge microbiology
NTHi was the most commonly cultured otopathogen from the
ear discharge of infants with either AOMwiP or CSOM. No ear dis-
charge was positive for serotypes 3, 6A, or 19A. Unexpectedly, the
proportion of NTHi, Sa, and NTHi + Spn positive ear discharge sam-
J. Beissbarth, N. Wilson, B. Arrowsmith et al. Vaccine 39 (2021) 2264–2273ples were all lower in the _SSS compared to the SSSP group at
7 months of age. As both groups had 3 doses of the PHiD-CV10 vac-
cine, differences in NTHi-related middle ear infection are difficult
to explain, also because there was no parallel difference in NTHi-
Np carriage. It is plausible that maternal antibody against NTHi
interfered with the infant responses to the earlier 1–2–4 month
schedule compared to the 2–4-6 month schedule. Whilst these
mothers were not vaccinated with a protein D vaccine, they may
have natural antibodies from prior exposure to NTHi, especially
those who live with other young children. We did not test maternal
antibodies in this trial, however, in unvaccinated infants at
2 months of age protein D antibody levels (trans-placental) were
very low [19].
We observed high density Sa infection in ear discharge of
infants at 2 months of age. Whilst ear canal contamination could
be the source of Sa in the ear discharge, our finding that peak Np
carriage of Sa (55%) is also at 2 months of age implies that the
Np may be a source at this early age.
For NTHi-OM, our study to 7 months of age was not able to con-
firm findings from observational studies in older post-booster dose
children in this population that reported a potential compartmen-
tal effect of PHiD-CV10 on reducing NTHi middle ear infection, in
the absence of an effect on Np carriage [12].
4.3. Mixed primary schedules
Prior to this study there were no trials describing mixed pri-
mary PCV schedules. Studies published during the time of this
RCT with mixed primary and booster series trials report immuno-
genicity outcomes (safety, reactogenicity, IgG, OPA and memory B
cells) [25,26], however, there are no other known published ran-
domised trials of mixed primary course PCV schedules.
4.4. Comparison with global experience, RCTs using PHiD-CV10 in a
primary series
Few PHiD-CV10 studies report nasopharyngeal carriage during
or at one month post primary infant series, and none are compar-
isons with PCV13. Infants in the Finnish RCT [27] received PHiD-
CV10 in a 3 dose primary series compared to a 2 dose series and
unvaccinated controls. They observed no significant difference in
Np carriage of any Spn, NTHi, Mc, or Sa. Post primary series, at
approximately 6 months of age, PHiD-CV10 serotype carriage
was 183/1803 (10.1%), 159/1289 (12.3%) and 237/1897 (12.5%)
and NTHi carriage was 51/1803 (2.8%), 33/1289 (2.6%) and
43/1897 (2.3%) in the 3-dose, 2-dose and control groups respec-
tively. An OM and carriage RCT in Panama [15] comparing a 3 dose
PHiD-CV10 primary series (2, 4, 6 months) with unvaccinated con-
trols also reported no difference in NTHi (5.7% (n = 788) vs 5.6%
(n = 784)), Sa, or Mc, with a significant difference in overall
PHiD-CV10 types, which was lower in the PHiD-CV10 group (12%
vs 16%) aged approximately 12 months. Both these studies report
much lower Np carriage rates than our cohort. Comparisons of
unvaccinated and a 2- or 3-dose primary series of PHiD-CV10 in
Nepal also showed no difference in pneumococcal Np carriage
(69/124, 55.6% vs 58/108, 53.7% vs 57/108. 25.8%) at 9 months of
age (post primary series) [28]. NTHi was not reported. A RCT in
the Netherlands [29] comparing PCV7 and PHiD-CV10 (both 2, 3,
4 month primary series) reported no significant difference at age
11–13 months in NTHi (138/255, 54% vs 296/512, 58%), overall
Spn (119/258, 46% vs 249/514, 48%), or serotype 19A (19/257, 7%
vs 33/514, 6%). The failure of primary series PHiD-CV10 to reduce
NTHi carriage seems to have been established in these trials, sup-
ported by cross-sectional data in diverse settings [4,30–32]. How-
ever, as none compare PHiD-CV10 with PCV13, impact on Np
carriage of serotypes 3, 6A, and 19A remain unclear. Our study2272had the potential to address this question, but concurrent intro-
duction of PCV13 to the national immunisation schedule at com-
mencement of our trial induced herd effects and thus diminished
carriage of these serotypes during the trial.
4.5. Neonatal vaccination
We report NP carriage rates of approximately 30% for NTHi and
Spn, and 47% for Mc at one month of age, indicating a possible role
for vaccination earlier than the 1 month of age first dose given in
this trial. There are two published trials of neonatal PCV7 vaccina-
tion, both in populations with high rates of Spn Np carriage and
IPD. Both studies showed that safety and reactogenicity outcomes
were not different between controls and vaccinees. The Kenyan
trial found no statistically significant difference in Np Spn carriage
at 18 or 36 weeks [33]. The Papua New Guinean study also found
no difference in overall Spn Np carriage or PCV7 VTs and non-
VTs at any age [34]. They report high rates of dense carriage, with
22% of infants positive for pneumococci at 1 week of age, and a
broad diversity of serotypes. There have been no neonatal trials
of PHiD-CV10 or PCV13. If the Australian Indigenous infant sched-
ule was to add a neonatal PCV, efficacy and safety studies would be
needed to confirm it could be co-administered with the neonatal
Hepatitis B vaccine.
4.6. Maternal vaccination
Maternal vaccination can provide antibodies to protect the
infant in the first weeks of life. A published study of maternal
pneumococcal polysaccharide vaccine in Indigenous mothers in
the NT, however the impact on infant Np Spn carriage was limited,
and there was evidence that maternal antibodies interfered with
infant response to PVC primary schedules [35]. A placebo con-
trolled maternal immunisation study of a 9 valent conjugate vac-
cine in the US also showed evidence of antibody interference,
with decreased responses to the infant primary series, which was
associated with increased rates of OM in the vaccinated group [36].
4.7. Limitations
Our few significant findings from exploratory analyses could be
significant due to chance alone, as we did not adjust for multiple
comparisons. However, the observations are of interest and con-
tribute to understanding early carriage.
The observed prevalence of serotype 19A carriage was lower
than predicted as a result of PCV13 introduction across Australia
in late 2011, this limited power to detect a significant difference.
The use of PCR and culture in combination may have increased
the detection sensitivity of ear discharge pathogens [7,37].
There were differences in the modifiable risk factors of smoking
and breastfeeding over time and between communities, however
the randomisation stratification at the community level was effec-
tive, and the factors were not dissimilar by vaccine group at both 1
and 6 months of age, and over time.5. Conclusions
This RCT reports that PHiD-CV10 does not reduce early NTHi
carriage in a high risk population compared to non-protein D
PCV13. We found no differences in VT- or non-VT Spn carriage
between 3-dose PHiD-CV10 or PCV13 schedules nor any difference
between these and a mixed 4-dose primary schedule. NTHi and
non-PCV serotypes are still major concerns for ear disease in this
population. NTHi was the main pathogen cultured from ear dis-
charge. These data suggest that multiple pathogens are driving
J. Beissbarth, N. Wilson, B. Arrowsmith et al. Vaccine 39 (2021) 2264–2273early OM episodes in this population. These infants continue to be
at high risk of early and persistent Np carriage and progression to
chronic OM with long term sequelae. Vaccines with efficacy and/or
herd effects against both NTHi and Spn nasopharyngeal carriage in
the first weeks of life will significantly improve the quality of life
for children who are currently at great disadvantage in terms of
language development, education, and later employment. In addi-
tion to, or in the absence of improved vaccines, other strategies to
prevent early exposure to infection will require cross-sector
investment to address vast gaps in social determinants of Aborigi-
nal and Torres Strait Islander health.
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